Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joint in axial SpA: a dual-energy CT study

Zhu, Junqing; Li, Aiwu; Jia, Ertao; Zhou, Yi; Xu, Juan; Chen, Shixian; Huang, Yinger; Xiao, Xiang; Li, Juan

doi:10.1186/s13075-017-1286-0

Table 4 Bivariate analysis between the grade of sacroiliac joint damage and clinical features^#

From: Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joint in axial SpA: a dual-energy CT study

Characteristics	Based on the left sacroiliac joint damage			Based on the right sacroiliac joint damage
Characteristics	Unadjusted OR	95% CI	p value	Unadjusted OR	95% CI	p value
Age, per year	1.016	0.985–1.047	0.324	1.025	0.994–1.057	0.121
Male, vs female	1.303	0.692–2.454	0.412	1.281	0.680–-2.412	0.444
AxSpA duration, per year	1.189	1.103–1.283	<0.001	1.195	1.108–1.289	<0.001
HLA-B27 positive, vs negative	1.248	0.546–2.850	0.599	1.197	0.524–2.732	0.670
ESR, per mm/h	1.024	1.011–1.037	<0.001	1.023	1.010–1.036	<0.001
CRP, per mg/l	1.045	1.027–1.063	<0.001	1.041	1.024–1.059	<0.001
Total back pain, per score	1.298	1.169–1.440	<0.001	1.263	1.139–1.399	<0.001
PGA of disease activity, per score	1.214	1.104–1.335	<0.001	1.221	1.110–1.343	<0.001
Pain and swelling of peripheral arthritis, per score	1.849	1.051–3.254	0.033	1.950	1.105–3.441	0.021
Duration of morning stiffness, per score	1.242	1.122–1.376	<0.001	1.234	1.115–1.367	<0.001
ASDAS, per score	1.716	1.397–2.107	<0.001	1.671	1.362–2.048	<0.001
BASFI, per score	3.188	2.330–4.364	<0.001	2.811	2.081–3.797	<0.001
Ever use of NSAIDs, vs never	1.893	0.740–4.842	0.183	1.372	0.543–3.471	0.504
Use of DMARDs ≥3 months, vs <3 months	1.922	0.751–4.922	0.173	1.967	0.769–5.034	0.158
Ever use of biologic DMARDs, vs never
≥ 12 months	0.143	0.057–0.357	<0.001	0.182	0.074–0.444	<0.001
≤ 12 months	0.274	0.127–0.592	0.001	0.244	0.113–0.531	<0.001
≤ 6 months	0.795	0.404–1.567	0.508	0.757	0.383–1.493	0.421
Never	NA	NA	NA	NA	NA	NA
Serum uric acid, per μmol/L	1.001	0.999–1.004	0.358	1.001	0.999–1.004	0.276
MSU crystallization positive, vs negative
Left sacroiliac joint	3.368	1.841–6.160	<0.001	NA	NA	NA
Right sacroiliac joint	NA	NA	NA	3.225	1.749–5.946	<0.001
Hip joint	0.715	0.415–1.232	0.227	0.674	0.390–1.163	0.156
Pubic symphysis	0.971	0.554–1.703	0.919	0.928	0.529–1.628	0.795
Volume of MSU crystallization, per cm³
Left sacroiliac joint	1.990	1.308–3.028	0.001	NA	NA	NA
Right sacroiliac joint	NA	NA	NA	1.470	1.125–1.922	0.005
Total volume at pelvis	1.015	0.983–1.047	0.370	1.015	0.983–1.047	0.367

AxSpA axial spondyloarthritis, ESR erythrocyte sedimentation rate, CRP C-reactive protein, PGA patient’s global assessment, ASDAS Ankylosing Spondylitis Disease Activity Score, BASFI Bath Ankylosing Spondylitis Functional Index, NSAIDs non-steroidal anti-inflammatory drugs, DMARDs disease-modifying anti-rheumatic drugs, MSU monosodium urate, OR odds ratios, 95% CI 95% confidence interval, NA not available
^#Including clinical variables and the DECT scans results

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us